Mineralys Therapeutics, Inc. Common Stock revenue growth has been varied year-over-year.

What is MLYS's revenue growth rate?

Historical revenue data is available for Mineralys Therapeutics, Inc. Common Stock to analyze growth trends.

How fast is MLYS earnings growing?

Earnings growth data is available for Mineralys Therapeutics, Inc. Common Stock analysis.

What is MLYS's profit margin?

Profit margin data is available for Mineralys Therapeutics, Inc. Common Stock.

MLYS Revenue & Earnings Growth Analysis 2026 - Is Mineralys Therapeutics, Inc. Common Stock Growing?

Growth Summary

Mineralys Therapeutics, Inc. Common Stock (MLYS) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Biotechnology industry.

Latest Revenue

$0.00

Net Income

$-177810000.00

5-Year Revenue CAGR

N/A

2 years of data

Net Margin

N/A

Latest period

Revenue Growth Over Time

Historical revenue and profitability trends for Mineralys Therapeutics, Inc. Common Stock

The chart above illustrates Mineralys Therapeutics, Inc. Common Stock's revenue trajectory over the past 2 years. The revenue pattern shows the challenges the company has faced in recent periods.

Year-over-Year Growth Rates

Annual percentage change in revenue and earnings

Growth rates provide insight into the momentum of Mineralys Therapeutics, Inc. Common Stock's business.

Profit Margin Trends

How efficiently Mineralys Therapeutics, Inc. Common Stock converts revenue into profit

Understanding Profit Margins

Profit margins reveal how much of each dollar of revenue Mineralys Therapeutics, Inc. Common Stock retains at different stages:

Gross Margin (N/A%): What remains after direct production costs
Operating Margin (N/A%): Profit from core operations before interest and taxes
Net Margin (N/A%): Final profit after all expenses

Future Growth Outlook

Analyst estimates and forward-looking indicators

EPS Estimate 2026

$-2.39

Current: $-3.66

EPS Estimate 2027

$-2.23

-6.6% expected growth

Price Target

$50.88

Analyst consensus

What Analysts Are Saying

Wall Street analysts project Mineralys Therapeutics, Inc. Common Stock to continue growing earnings in the coming year. The consensus analyst rating is 4.75 based on 8 analysts.

Growth Analysis Conclusion

Based on our comprehensive analysis, Mineralys Therapeutics, Inc. Common Stock (MLYS) demonstrates declining growth characteristics.

Key Takeaways:

Revenue Growth:
Profitability: shows the company is investing in growth over short-term profits
Efficiency:

Investment Considerations

This growth analysis provides a comprehensive view of Mineralys Therapeutics, Inc. Common Stock's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.